# US 2009/0270362 A1 · Bicyclic mglur5 positive allosteric modulators and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270362 A1
- Document ID: US20090270362A1
- Status: Published application
- Kind: A1
- Application number: 12/263,224
- Filed: 2008-10-31
- Published: 2009-10-29
- Earliest claimed: 2007-11-02
- Assignees: Vanderbilt University
- Inventors: P. Jeffrey Conn; Craig W. Lindsley; Charles David Weaver; Alice L. Rodriguez; Colleen M. Niswender; Carrie K. Jones; Richard Williams
- Web page: https://patentgrep.com/patent/US20090270362A1

## CPC

- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07D 209/46: with an oxygen atom in position 1
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 217/24: Oxygen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In one aspect, the invention relates to bicyclic MGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, comprising:
a. an isoindolin-1-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl;
b. an isoindoline-1,3-dione derivative having a structure:
wherein R1 is hydrogen or is selected from optionally substituted C1-C12 alkyl, optionally substituted C1-C12 heteroalkyl, optionally substituted C3-C12 cycloalkyl, or optionally substituted C3-C12 heterocycloalkyl, with the proviso that R1 does not comprise silicon; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl, and with the proviso that if R1 is methyl, then R5 is an organic radical comprising 4 to 14 carbon atoms;
c. a 3,4-dihydroisoquinolin-1(2H)-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms;
d. an isoquinoline-1,3(2H,4H)-dione derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that R5 does not comprise a triphenylamine residue or a benzimidamide residue; or
e. a bicyclic compound having a structure:
wherein n is 2, 3 or 4;
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R2a and R2b together comprise ═O or ═S or each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
wherein Y1 is selected from N and C—R4;
wherein Y2 is selected from N and C—H;
wherein each R3a and R3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R4 is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms and is selected from:
wherein R7a and R7b together form an optionally substituted carbocyclic or heterocyclic ring having from two to five carbons or are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 5 carbon atoms selected from optionally substituted C1-C5 alkyl or C2-C5 alkenyl or C2-C5 alkynyl, optionally substituted C1-C5 heteroalkyl or C2-C5 heteroalkenyl or C2-C5 heteroalkynyl, optionally substituted C3-C5 cycloalkyl or C3-C5 cycloalkenyl, optionally substituted C3-C5 heterocycloalkyl or C3-C5 heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl; and
wherein R8 is selected from hydrogen, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, and optionally substituted heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1,
wherein R1 is an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CH2)m-aryl or —(CH2)m-heterocycle, wherein m is 1, 2, 3 or 4;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R4, when present, is an organic radical comprising 1 to 12 carbon atoms independently selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl.

### Claim 3 (depends on 1)

The compound of claim 1 comprising a structure having a formula:

### Claim 4 (depends on 1)

The compound of claim 1 comprising a structure having a formula:
wherein R7a and R7b together form an optionally substituted carbocyclic or heterocyclic ring having from two to five carbons or are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 5 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.

### Claim 5 (depends on 1)

The compound of claim 1 comprising a structure having a formula:
wherein R7a and R7b are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 5 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.

### Claim 6 (depends on 1)

The compound of claim 1 comprising a structure having a formula:

### Claim 7 (depends on 1)

The compound of claim 1 comprising a structure having a formula:
wherein R8 is selected from hydrogen and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, and optionally substituted heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, selected from:

### Claim 9 (depends on 1)

The compound of claim 1, selected from:

### Claim 10 (depends on 1)

The compound of claim 1, selected from:

### Claim 11 (depends on 1)

The compound of claim 1, selected from:

### Claim 12

A method for preparing a compound having a structure:
wherein n is 0, 1, 2, 3 or 4;
wherein Y1 and Y2 are independently selected from C and N;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms selected from optionally substituted C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted amido;
wherein R1 is selected from hydrogen and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CH2)m-aryl or —(CH2)m-heterocycle, wherein m is 1, 2, 3 or 4;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R4 comprises one, two, or three substituents independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; and
or a pharmaceutically acceptable salt or N-oxide thereof,
comprising the step of coupling a first reactant with a second reactant, thereby forming linking moiety L.

### Claim 13 (depends on 12)

The method of claim 12, wherein the method comprises the steps of:
a. providing a first reactant having a structure represented by a formula:
wherein n is 0, 1, 2, 3 or 4;
wherein Y1 and Y2 are independently selected from C and N;
wherein R1 is selected from hydrogen and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CH2)m-aryl or —(CH2)m-heterocycle, wherein m is 1, 2, 3 or 4;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R4 comprises one, two, or three substituents independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl; and
wherein X1 comprises a halide, a pseudohalide, a carboxylic acid, a carboxylic acid derivative, a terminal acetylene moiety, an activated vinyl moiety, a N′-hydroxybenzimidamide, or a primary or secondary amine;
or a pharmaceutically acceptable salt or N-oxide thereof,
b. providing a second reactant having a structure represented by a formula:
wherein R5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; and
wherein X2 comprises a halide, a pseudohalide, a carboxylic acid, a carboxylic acid derivative, a terminal acetylene moiety, an activated vinyl moiety, a N′-hydroxybenzimidamide, or a primary or secondary amine;
c. coupling the first reactant with the second reactant, thereby forming linking moiety L, to provide a compound having a structure represented by a formula:
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms selected from optionally substituted C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted amido;
wherein, when X1 is halide or pseudohalide, X2 is a terminal acetylene moiety, or an activated vinyl moiety;
wherein, when X1 is a carboxylic acid or a carboxylic acid derivative, X2 is a N′-hydroxybenzimidamide, or a primary or secondary amine;
wherein, when X2 is halide or pseudohalide, X1 is a terminal acetylene moiety, or an activated vinyl moiety;
wherein, when X2 is a carboxylic acid or a carboxylic acid derivative, X1 is a N′-hydroxybenzimidamide, or a primary or secondary amine; and
d. optionally, if R1 is hydrogen, alkylating the lactam or imide moiety.

### Claim 14 (depends on 12)

The method of claim 12, wherein the method comprises the steps of:
a. providing a reactant comprising an anhydride having a structure represented by a formula:
wherein n is 0 or 1;
wherein Y1 and Y2 are independently selected from C and N;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R4 comprises one, two, or three substituents independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; and
wherein X1 comprises a halide or a pseudohalide or -L-R5, wherein L is an organic divalent radical comprising 1 to 7 carbon atoms and R5 is an organic radical comprising 4 to 14 carbon atoms;
or a pharmaceutically acceptable salt or N-oxide thereof,
b. treating the reactant with ammonia or a primary amine to afford a compound having a structure represented by a formula:
c. optionally, if R1 is hydrogen, alkylating the imide moiety.

### Claim 15 (depends on 12)

The method of claim 12, wherein the method comprises the steps of:
a. providing a reactant comprising a lactone having a structure represented by a formula:
wherein n is 0, 1, 2, 3 or 4;
wherein Y1 and Y2 are independently selected from C and N;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R4 comprises one, two, or three substituents independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; and
wherein X1 comprises a halide or a pseudohalide or -L-R5, wherein L is an organic divalent radical comprising 1 to 7 carbon atoms and R5 is an organic radical comprising 4 to 14 carbon atoms;
or a pharmaceutically acceptable salt or N-oxide thereof;
b. treating the reactant with ammonia or a primary amine to afford an intermediate having a structure represented by a formula:
c. cyclizing the intermediate to afford a compound having a structure represented by a formula:
d. optionally, if R1 is hydrogen, alkylating the lactam moiety.

### Claim 16

A method for potentiation of metabotropic glutamate receptor activity in a mammal comprising the step of administering to the mammal at least one compound having a structure:
wherein n is 0, 1, 2, 3 or 4;
wherein Y1 and Y2 are independently selected from C and N;
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R4 comprises one, two, or three substituents independently present as hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to potentiate metabotropic glutamate receptor activity in the mammal.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound comprises:
a. an isoindolin-1-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl;
b. an isoindoline-1,3-dione derivative having a structure:
wherein R1 is hydrogen or is selected from optionally substituted C1-C12 alkyl, optionally substituted C1-C12 heteroalkyl, optionally substituted C3-C12 cycloalkyl, or optionally substituted C3-C12 heterocycloalkyl, with the proviso that R1 does not comprise silicon; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl, and with the proviso that if R1 is methyl, then R5 is an organic radical comprising 4 to 14 carbon atoms;
c. a 3,4-dihydroisoquinolin-1(2H)-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms;
d. an isoquinoline-1,3(2H,4H)-dione derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that R5 does not comprise a triphenylamine residue or a benzimidamide residue; or
e. a bicyclic compound having a structure:
wherein n is 2, 3 or 4;
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R2a and R2b together comprise ═O or ═S or each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
wherein Y1 is selected from N and C—R4;
wherein Y2 is selected from N and C—H;
wherein each R3a and R3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R4 is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms and is selected from:
wherein R7a and R7b together form an optionally substituted carbocyclic or heterocyclic ring having from two to five carbons or are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 5 carbon atoms selected from optionally substituted C1-C5 alkyl or C2-C5 alkenyl or C2-C5 alkynyl, optionally substituted C1-C5 heteroalkyl or C2-C5 heteroalkenyl or C2-C5 heteroalkynyl, optionally substituted C3-C5 cycloalkyl or C3-C5 cycloalkenyl, optionally substituted C3-C5 heterocycloalkyl or C3-C5 heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl; and
wherein R8 is selected from hydrogen, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, and optionally substituted heteroaryl.

### Claim 18 (depends on 16)

The method of claim 16, wherein the mammal is a human.

### Claim 19 (depends on 16)

The method of claim 16, wherein the mammal has been diagnosed with a need for potentiation of metabotropic glutamate receptor activity prior to the administering step.

### Claim 20

A method for the treatment of a disorder in a mammal comprising the step of administering to the mammal at least one compound having a structure:
wherein n is 0, 1, 2, 3 or 4;
wherein Y1 and Y2 are independently selected from C and N;
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R2a and R2b, when present, together comprise ═O or ═S or each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R3a and R3b together comprise ═O or ═S or each R3a and R3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R4 comprises one, two, or three substituents independently present as hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the disorder in the mammal.

### Claim 21 (depends on 20)

The method of claim 20, wherein the compound comprises:
a. an isoindolin-1-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl;
b. an isoindoline-1,3-dione derivative having a structure:
wherein R1 is hydrogen or is selected from optionally substituted C1-C12 alkyl, optionally substituted C1-C12 heteroalkyl, optionally substituted C3-C12 cycloalkyl, or optionally substituted C3-C12 heterocycloalkyl, with the proviso that R1 does not comprise silicon; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that if R1 is hydrogen, then R5 is optionally substituted phenyl or optionally substituted pyridinyl, and with the proviso that if R1 is methyl, then R5 is an organic radical comprising 4 to 14 carbon atoms;
c. a 3,4-dihydroisoquinolin-1(2H)-one derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms;
d. an isoquinoline-1,3(2H,4H)-dione derivative having a structure:
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms, with the proviso that R5 does not comprise a triphenylamine residue or a benzimidamide residue; or
e. a bicyclic compound having a structure:
wherein n is 2, 3 or 4;
wherein R1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R2a and R2b together comprise ═O or ═S or each R2a and R2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
wherein Y1 is selected from N and C—R4;
wherein Y2 is selected from N and C—H;
wherein each R3a and R3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R4 is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms;
wherein L is an organic divalent radical comprising 1 to 7 carbon atoms and is selected from:
wherein R7a and R7b together form an optionally substituted carbocyclic or heterocyclic ring having from two to five carbons or are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, and an organic radical comprising 1 to 5 carbon atoms selected from optionally substituted C1-C5 alkyl or C2-C5 alkenyl or C2-C5 alkynyl, optionally substituted C1-C5 heteroalkyl or C2-C5 heteroalkenyl or C2-C5 heteroalkynyl, optionally substituted C3-C5 cycloalkyl or C3-C5 cycloalkenyl, optionally substituted C3-C5 heterocycloalkyl or C3-C5 heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl; and
wherein R8 is selected from hydrogen, and an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, and optionally substituted heteroaryl.

### Claim 22 (depends on 20)

The method of claim 20, wherein the disorder is a neurological and/or psychiatric disorder associated with glutamate dysfunction.

### Claim 23 (depends on 20)

The method of claim 20, wherein the disorder is selected from dementia, delirium, amnestic disorders, age-related cognitive decline, schizophrenia, psychosis including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, substance-related disorder, movement disorders, epilepsy, chorea, pain, migraine, diabetes, dystonia, obesity, eating disorders, brain edema, sleep disorder, narcolepsy, anxiety, affective disorder, panic attacks, unipolar depression, bipolar disorder, and psychotic depression.

### Claim 24 (depends on 20)

The method of claim 20, wherein the mammal is a human.

### Claim 25 (depends on 20)

The method of claim 20, wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.
